Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arbutus Biopharma Corp (ABUS)
USD4.48
-0.13 (-2.73%)
US NASDAQ Healthcare Biotechnology
Address
701 Veterans Circle 18974
Warminster, PA, US
Warminster, PA, US
CEO
Lindsay Androski
Website
arbutusbio.com
IPO
2007-07-26
CIK 1447028 ISIN CA03879J1003
Description
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.48
-0.13 (-2.73%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.63
Float Shares
156.22M
Free Float %
79.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.82% | -0.69% | -1.37% | +8.29% | -5.48% | -10.40% | +35.11% | +68.36% | +72.40% | -0.92% | -31.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
4.48
Low
8.50
+89.6%
Consensus
8.50
+89.6%
Median
8.50
+89.6%
High
8.50
+89.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
8.50
+89.6%
|
Quality scores
Altman Z-Score
8.30
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+128.2% ★ Q1'26: +10,054.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+55.3% ★ Q1'26: +769.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-261.4% Q1'26: -4.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-192.1% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.2% ★ Q1'26: +2.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.87M
est: 19.78M (+25.8%)
|
1.50M
est: 2.02M (-25.8%)
|
10.70M
est: 8.78M (+21.8%)
|
5.90M
est: 5.33M (+10.7%)
|
6.01M
est: 11.19M (-46.3%)
|
6.91M
est: 6.52M (+6.0%)
|
10.99M
est: 10.68M (+2.9%)
|
39.02M
est: 38.96M (+0.1%)
|
18.14M
est: 10.06M (+80.3%)
|
6.17M
est: 6.18M (-0.2%)
|
14.08M
est: 13.63M (+3.3%)
|
2.60M
2.60M – 2.60M
-80.9% YoY
|
8.83M
8.83M – 8.83M
+239.7% YoY
|
55.95M
55.95M – 55.95M
+533.5% YoY
|
173.53M
173.53M – 173.53M
+210.2% YoY
|
| EBITDA |
-76.72M
est: -19.78M (-287.9%)
|
-488.07M
est: -2.02M (-24,046.7%)
|
-106.45M
est: -8.78M (-1,111.9%)
|
-58.95M
est: -5.33M (-1,006.5%)
|
-162.24M
est: -11.19M (-1,350.0%)
|
-57.76M
est: -6.52M (-785.4%)
|
-71.64M
est: -10.68M (-571.0%)
|
-61.86M
est: -38.96M (-58.8%)
|
-70.99M
est: -10.06M (-605.6%)
|
-68.40M
est: -6.18M (-1,006.5%)
|
-26.69M
est: -13.63M (-95.8%)
|
-2.60M
-2.60M – -2.60M
+80.9% YoY
|
-8.83M
-8.83M – -8.83M
-239.7% YoY
|
-55.95M
-55.95M – -55.95M
-533.5% YoY
|
-173.53M
-173.53M – -173.53M
-210.2% YoY
|
| EBIT |
-78.90M
est: -19.78M (-299.0%)
|
-489.17M
est: -2.02M (-24,100.7%)
|
-108.47M
est: -8.78M (-1,135.0%)
|
-61.12M
est: -5.33M (-1,047.1%)
|
-164.27M
est: -11.19M (-1,368.1%)
|
-59.73M
est: -6.52M (-815.7%)
|
-73.39M
est: -10.68M (-587.5%)
|
-63.29M
est: -38.96M (-62.4%)
|
-72.39M
est: -10.06M (-619.5%)
|
-69.78M
est: -6.18M (-1,028.8%)
|
-27.05M
est: -13.63M (-98.5%)
|
-2.60M
-2.60M – -2.60M
+80.9% YoY
|
-8.83M
-8.83M – -8.83M
-239.7% YoY
|
-55.95M
-55.95M – -55.95M
-533.5% YoY
|
-173.53M
-173.53M – -173.53M
-210.2% YoY
|
| Net Income |
-61.12M
est: -284.60M (+78.5%)
|
-384.10M
est: -804.61M (+52.3%)
|
-84.40M
est: -243.89M (+65.4%)
|
-57.10M
est: -219.76M (+74.0%)
|
-153.72M
est: -506.34M (+69.6%)
|
-63.75M
est: -181.90M (+65.0%)
|
-76.25M
est: -159.99M (+52.3%)
|
-69.46M
est: -83.90M (+17.2%)
|
-72.85M
est: -84.42M (+13.7%)
|
-69.92M
est: -74.34M (+5.9%)
|
-33.50M
est: -35.97M (+6.9%)
|
-22.03M
-22.03M – -22.03M
+38.7% YoY
|
-9.58M
-9.58M – -9.58M
+56.5% YoY
|
-26.82M
-26.82M – -26.82M
-180.0% YoY
|
65.14M
65.14M – 65.14M
+342.9% YoY
|
| SGA |
26.44M
est: 35.54M (-25.6%)
|
39.40M
est: 3.63M (+984.7%)
|
16.10M
est: 15.78M (+2.0%)
|
16.00M
est: 9.57M (+67.1%)
|
17.73M
est: 20.11M (-11.8%)
|
14.85M
est: 11.72M (+26.6%)
|
17.14M
est: 19.18M (-10.7%)
|
17.83M
est: 70.02M (-74.5%)
|
22.48M
est: 16.03M (+40.2%)
|
22.11M
est: 9.85M (+124.4%)
|
15.89M
est: 21.72M (-26.8%)
|
4.14M
4.14M – 4.14M
-80.9% YoY
|
14.07M
14.07M – 14.07M
+239.7% YoY
|
89.14M
89.14M – 89.14M
+533.5% YoY
|
276.49M
276.49M – 276.49M
+210.2% YoY
|
| EPS |
-1.34
est: -1.53 (+12.6%)
|
-7.24
est: -4.34 (-67.0%)
|
-1.54
est: -1.31 (-17.2%)
|
-1.03
est: -1.18 (+13.0%)
|
-2.69
est: -2.73 (+1.4%)
|
-0.86
est: -0.98 (+12.2%)
|
-0.73
est: -0.86 (+15.3%)
|
-0.46
est: -0.45 (-1.8%)
|
-0.44
est: -0.44 (+0.1%)
|
-0.38
est: -0.39 (+2.1%)
|
-0.17
est: -0.19 (+9.5%)
|
-0.12
-0.12 – -0.12
+38.7% YoY
|
-0.05
-0.05 – -0.05
+56.5% YoY
|
-0.14
-0.14 – -0.14
-180.0% YoY
|
0.34
0.34 – 0.34
+342.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-36.04M
OE per share TTM
-0.19
Owner's Yield
-4.36%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
45.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
65
Total invested
80.71M
Insider transactions (90d)
0
Beneficial owners (>5%)
36
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Morgan Stanley | 19.39M | 10.30% | — | 19.38M | — | 19.38M | HC, CO | Delaware. | 2024-06-10 | ↗ |
| 2 | Morgan Stanley Investment Management Inc. | 19.12M | 10.10% | — | 19.12M | — | 19.12M | IA, CO | Delaware. | 2024-06-10 | ↗ |
| 3 | David Salanic | 12.87M | 6.80% | — | — | — | 12.87M | HC, IN | — | 2024-05-09 | ↗ |
| 4 | Joseph Kaplan | 12.87M | 6.80% | — | — | — | 12.87M | HC, IN | — | 2024-05-09 | ↗ |
| 5 | Whitefort Capital GP, LLC | 12.87M | 6.80% | — | — | — | 12.87M | OO | — | 2024-05-09 | ↗ |
| 6 | Whitefort Capital Management GP, LLC | 12.87M | 6.80% | — | — | — | 12.87M | OO | — | 2024-05-09 | ↗ |
| 7 | Whitefort Capital Management, LP | 12.87M | 6.80% | — | — | — | 12.87M | IA, PN | — | 2024-05-09 | ↗ |
| 8 | Whitefort Capital Master Fund, LP | 12.87M | 6.80% | — | — | — | 12.87M | PN | — | 2024-05-09 | ↗ |
| 9 | Sina Toussi | 9.50M | 5.70% | 9.50M | — | 9.50M | — | HC, IN | United States | 2023-11-21 | ↗ |
| 10 | Two Seas Capital GP LLC | 9.50M | 5.70% | 9.50M | — | 9.50M | — | HC, OO | Delaware | 2023-11-21 | ↗ |
| 11 | Two Seas Capital LP | 9.50M | 5.70% | 9.50M | — | 9.50M | — | IA, PN | Delaware | 2023-11-21 | ↗ |
| 12 | RTW Investments, LP | 5.98M | 7.05% | — | 5.98M | — | 5.98M | IA, PN, OO | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 13 | Roderick Wong | 5.98M | 7.05% | — | 5.98M | — | 5.98M | HC, IN | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 14 | S | 5.67M | 9.12% | — | 5.67M | — | — | IA, OO | — | 2020-02-14 | ↗ |
| 15 | RTW Master Fund, Ltd. | 4.53M | 5.34% | — | 4.53M | — | 4.53M | CO | OR PLACE OF ORGANIZATION | 2021-02-12 | ↗ |
| 16 | IV”) | 3.71M | 6.50% | 3.71M | 3.71M | 3.71M | 3.71M | PN | Delaware | 2020-02-14 | ↗ |
| 17 | S James Tananbaum (“Tananbaum”) | 3.71M | 6.50% | 3.71M | 3.71M | 3.71M | 3.71M | IN | United States | 2020-02-14 | ↗ |
| 18 | Morgan Stanley Capital Services LLC | 1.40M | 1.70% | — | 1.40M | — | 1.40M | CO | Delaware. | 2021-02-10 | ↗ |
| 19 | PRIMECAP Management Company 95-3868081 | 600.0K | 1.06% | 600.0K | — | 600.0K | — | IA | 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 | 2019-11-05 | ↗ |
| 20 | EcoR1 Capital, LLC | — | 11.00% | — | — | — | — | IA, OO | Delaware | 2020-02-14 | ↗ |
| 21 | Oleg Nodelman | — | 11.00% | — | — | — | — | HC, IN | United States | 2020-02-14 | ↗ |
| 22 | David C. Ott | — | 0.00% | — | — | — | 10.00 | IN | United States | 2019-07-12 | ↗ |
| 23 | Dr. Andrew Lo | — | 0.00% | — | — | — | 10.00 | IN | United States | 2019-07-17 | ↗ |
| 24 | Foresite Capital Fund IV, L.P. (“FCF IV”) | — | 0.00% | — | — | — | — | PN | Delaware | 2021-02-16 | ↗ |
| 25 | Foresite Capital Management IV, LLC (“FCM IV”) | — | 0.00% | — | — | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 26 | James Tananbaum (“Tananbaum”) | — | 0.00% | — | — | — | — | IN | United States | 2021-02-16 | ↗ |
| 27 | O. Andreas Halvorsen | — | 0.00% | — | — | — | 10.00 | IN | Norway | 2019-07-12 | ↗ |
| 28 | Rose S. Shabet | — | 0.00% | — | — | — | 10.00 | IN | United States | 2019-07-12 | ↗ |
| 29 | VGE III Portfolio Ltd. | — | 0.00% | — | — | — | 10.00 | CO | Cayman Islands | 2019-07-12 | ↗ |
| 30 | Viking Global Equities II LP | — | 0.00% | — | — | — | 10.00 | PN | Delaware | 2019-07-12 | ↗ |
| 31 | Viking Global Equities LP | — | 0.00% | — | — | — | 10.00 | PN | Delaware | 2019-07-12 | ↗ |
| 32 | Viking Global Equities Master Ltd. | — | 0.00% | — | — | — | 10.00 | CO | Cayman Islands | 2019-07-12 | ↗ |
| 33 | Viking Global Investors LP | — | 0.00% | — | — | — | 10.00 | PN | Delaware | 2019-07-12 | ↗ |
| 34 | Viking Global Opportunities Illiquid Investments Sub-Master LP | — | 0.00% | — | — | — | 10.00 | PN | Cayman Islands | 2019-07-12 | ↗ |
| 35 | Viking Global Performance LLC | — | 0.00% | — | — | — | 10.00 | OO | Delaware | 2019-07-12 | ↗ |
| 36 | Viking Long Fund GP LLC | — | 0.00% | — | — | — | 10.00 | OO | Delaware | 2019-07-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
65
-125 vs prev Q
New positions
16
Closed positions
129
Increased
28
Reduced
13
Put/Call ratio
0.87
Calls held
230.0K
Puts held
200.0K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 26.70M +2.3M (+9.2%) | 128.44M +17.4M (+15.7%) | 13.92% +1.159 pp | 0.01% +0.001 pp | USD3.21 +49.8% | 42 qtrs — |
| 2 | WHITEFORT CAPITAL MANAGEMENT, LP | 13.34M +— (+0.0%) | 64.18M +3.6M (+5.9%) | 6.96% -0.008 pp | 16.41% -1.498 pp | USD2.48 +94.0% | 13 qtrs — |
| 3 | BLACKROCK, INC. | 13.05M +375.4K (+3.0%) | 62.78M +5.2M (+9.1%) | 6.81% +0.188 pp | 0.00% +0.000 pp | USD3.84 +25.3% | 6 qtrs — |
| 4 | TWO SEAS CAPITAL LP | 12.59M +1.6M (+14.5%) | 60.55M +10.7M (+21.3%) | 6.56% +0.826 pp | 1.25% +0.447 pp | USD3.06 +57.2% | 17 qtrs — |
| 5 | VANGUARD GROUP INC | 9.24M +251.4K (+2.8%) | 44.46M +3.6M (+8.9%) | 4.82% +0.126 pp | 0.00% +0.000 pp | USD3.21 +49.8% | 31 qtrs — |
| 6 | STATE STREET CORP | 5.91M +1.8M (+44.2%) | 28.42M +9.8M (+52.7%) | 3.08% +0.941 pp | 0.00% +0.000 pp | USD3.79 +26.9% | 42 qtrs — |
| 7 | ADAR1 CAPITAL MANAGEMENT, LLC | 5.42M +2.5M (+86.5%) | 26.05M +12.9M (+97.6%) | 2.82% +1.308 pp | 1.91% +0.675 pp | USD3.83 +25.6% | 9 qtrs — |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.34M -675.0K (-13.5%) | 20.88M -1.9M (-8.3%) | 2.26% -0.355 pp | 0.03% -0.005 pp | USD3.63 +32.5% | 8 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 3.68M +11.1K (+0.3%) | 17.69M +1.0M (+6.3%) | 1.92% +0.004 pp | 0.00% +0.000 pp | USD3.00 +60.3% | 42 qtrs — |
| 10 | WOODLINE PARTNERS LP | 2.19M +21.0K (+1.0%) | 10.52M +685.5K (+7.0%) | 1.14% +0.010 pp | 0.04% -0.006 pp | USD3.24 +48.5% | 12 qtrs — |
| 11 | BLACKBARN CAPITAL PARTNERS LP | 1.85M -150.0K (-7.5%) | 8.90M -181.5K (-2.0%) | 0.96% -0.080 pp | 0.59% -0.065 pp | USD2.69 +78.8% | 8 qtrs — |
| 12 | BANK OF AMERICA CORP /DE/ | 1.83M +381.9K (+26.3%) | 8.82M +2.2M (+33.8%) | 0.96% +0.198 pp | 0.00% +0.000 pp | USD3.72 +29.3% | 42 qtrs — |
| 13 | RUBRIC CAPITAL MANAGEMENT LP | 1.58M +— (+0.0%) | 7.58M +425.4K (+5.9%) | 0.82% -0.001 pp | 0.09% +0.010 pp | USD3.12 +54.2% | 7 qtrs — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.56M +287.4K (+22.5%) | 7.51M +1.7M (+29.8%) | 0.81% +0.149 pp | 0.00% +0.000 pp | USD3.80 +26.6% | 22 qtrs — |
| 15 | ADVISOR GROUP HOLDINGS, INC. | 1.35M +9.7K (+0.7%) | 6.48M +515.3K (+8.6%) | 0.70% +0.004 pp | 0.01% +0.001 pp | USD1.08 +345.4% | 24 qtrs — |
| 16 | NORTHERN TRUST CORP | 1.24M -52.7K (-4.1%) | 5.95M +94.5K (+1.6%) | 0.64% -0.028 pp | 0.00% +0.000 pp | USD2.99 +60.9% | 23 qtrs — |
| 17 | STEMPOINT CAPITAL LP | 986.8K +781.4K (+380.4%) | 4.75M +3.8M (+409.0%) | 0.51% +0.407 pp | 0.81% +0.627 pp | USD4.75 +1.3% | 4 qtrs — |
| 18 | UBS ASSET MANAGEMENT AMERICAS INC | 890.9K +890.9K (+100.0%) | 4.29M +4.3M (+100.0%) | 0.46% +0.465 pp | 0.00% +0.001 pp | USD4.81 +0.0% | 6 qtrs — |
| 19 | RANGELEY CAPITAL, LLC | 840.0K +— (+0.0%) | 4.04M +226.8K (+5.9%) | 0.44% -0.001 pp | 3.36% +0.056 pp | USD3.27 +47.1% | 5 qtrs — |
| 20 | BANK OF MONTREAL /CAN/ | 766.7K +1.4K (+0.2%) | 3.69M +213.3K (+6.1%) | 0.40% +0.000 pp | 0.00% 0.000 pp | USD3.70 +30.0% | 41 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 738.6K -1.4M (-66.0%) | 3.55M -6.3M (-64.0%) | 0.39% -0.750 pp | 0.00% -0.001 pp | USD3.39 +41.9% | 42 qtrs — |
| 22 | HUDSON BAY CAPITAL MANAGEMENT LP | 675.0K -125.0K (-15.6%) | 3.25M -385.3K (-10.6%) | 0.35% -0.066 pp | 0.01% -0.001 pp | USD2.80 +71.8% | 36 qtrs — |
| 23 | DIADEMA PARTNERS LP | 548.6K +32.3K (+6.3%) | 2.64M +294.8K (+12.6%) | 0.29% +0.017 pp | 0.45% -0.145 pp | USD4.56 +5.5% | 2 qtrs — |
| 24 | AFFINITY ASSET ADVISORS, LLC | 521.9K +310.4K (+146.8%) | 2.51M +1.6M (+161.4%) | 0.27% +0.162 pp | 0.14% +0.059 pp | USD4.67 +3.0% | 3 qtrs — |
| 25 | QUINN OPPORTUNITY PARTNERS LLC | 514.5K +— (+0.0%) | 2.47M +138.9K (+5.9%) | 0.27% 0.000 pp | 0.10% -0.061 pp | USD3.45 +39.4% | 7 qtrs — |
| 26 | WESTERN STANDARD LLC | 507.9K +— (+0.0%) | 2.44M +137.1K (+5.9%) | 0.26% 0.000 pp | 1.13% +0.443 pp | USD4.54 +5.9% | 2 qtrs — |
| 27 | KENNEDY CAPITAL MANAGEMENT LLC | 505.1K -5.0 (0.0%) | 2.43M +136.4K (+5.9%) | 0.26% 0.000 pp | 0.05% +0.001 pp | USD3.16 +52.2% | 12 qtrs — |
| 28 | WELLINGTON MANAGEMENT GROUP LLP | 474.4K -39.7K (-7.7%) | 2.28M -52.3K (-2.2%) | 0.25% -0.021 pp | 0.00% +0.000 pp | USD2.68 +79.5% | 8 qtrs — |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 473.6K +101.5K (+27.3%) | 2.28M +588.7K (+34.8%) | 0.25% +0.053 pp | 0.00% +0.000 pp | USD3.82 +25.9% | 34 qtrs — |
| 30 | FREESTONE CAPITAL HOLDINGS, LLC | 442.5K +— (+0.0%) | 2.13M +119.5K (+5.9%) | 0.23% 0.000 pp | 0.06% +0.001 pp | USD3.12 +54.2% | 7 qtrs — |
| 31 | BANK OF NEW YORK MELLON CORP | 387.9K -11.2K (-2.8%) | 1.87M +53.7K (+3.0%) | 0.20% -0.006 pp | 0.00% +0.000 pp | USD3.23 +48.9% | 22 qtrs — |
| 32 | BARCLAYS PLC | 356.7K +84.7K (+31.1%) | 1.72M +668.3K (+63.8%) | 0.19% +0.044 pp | 0.00% +0.000 pp | USD3.70 +30.0% | 21 qtrs — |
| 33 | SABA CAPITAL MANAGEMENT, L.P. | 347.9K -330.9K (-48.7%) | 1.67M -1.4M (-45.7%) | 0.18% -0.173 pp | 0.05% -0.035 pp | USD3.01 +59.8% | 8 qtrs — |
| 34 | CITIGROUP INC | 339.2K -100.0K (-22.8%) | 1.63M -362.4K (-18.2%) | 0.18% -0.052 pp | 0.00% 0.000 pp | USD3.51 +37.0% | 12 qtrs — |
| 35 | SWISS NATIONAL BANK | 283.4K +7.1K (+2.6%) | 1.36M +108.8K (+8.7%) | 0.15% +0.004 pp | 0.00% +0.000 pp | USD3.87 +24.3% | 6 qtrs — |
| 36 | LEDGEWOOD WEALTH ADVISORS, LLC | 278.4K +— (+0.0%) | 1.34M +75.2K (+5.9%) | 0.15% 0.000 pp | 0.77% +0.023 pp | USD2.50 +92.4% | 9 qtrs — |
| 37 | MURCHINSON LTD. | 275.0K +75.0K (+37.5%) | 1.32M +414.8K (+45.7%) | 0.14% +0.039 pp | 0.21% +0.098 pp | USD4.61 +4.3% | 2 qtrs — |
| 38 | NUVEEN, LLC | 257.9K +— (+0.0%) | 1.24M +69.6K (+5.9%) | 0.13% 0.000 pp | 0.00% +0.000 pp | USD3.39 +41.9% | 4 qtrs — |
| 39 | INVESCO LTD. | 247.3K +37.6K (+17.9%) | 1.19M +237.5K (+25.0%) | 0.13% +0.020 pp | 0.00% +0.000 pp | USD3.57 +34.7% | 19 qtrs — |
| 40 | D. E. SHAW & CO., INC. | 231.8K +41.8K (+22.0%) | 1.11M +252.4K (+29.3%) | 0.12% +0.022 pp | 0.00% +0.000 pp | USD4.33 +11.1% | 3 qtrs — |
| 41 | RHUMBLINE ADVISERS | 183.3K -28.5K (-13.5%) | 881.4K -80.1K (-8.3%) | 0.10% -0.015 pp | 0.00% 0.000 pp | USD2.97 +62.0% | 19 qtrs — |
| 42 | WELLS FARGO & COMPANY/MN | 167.0K +71.6K (+75.0%) | 803.4K +370.0K (+85.4%) | 0.09% +0.037 pp | 0.00% +0.000 pp | USD3.90 +23.3% | 42 qtrs — |
| 43 | QUBE RESEARCH & TECHNOLOGIES LTD | 157.6K -57.5K (-26.7%) | 758.0K -218.3K (-22.4%) | 0.08% -0.030 pp | 0.00% 0.000 pp | USD3.44 +39.8% | 6 qtrs — |
| 44 | NOMURA HOLDINGS INC | 150.0K +— (+0.0%) | 721.5K +40.5K (+5.9%) | 0.08% 0.000 pp | 0.00% 0.000 pp | USD3.84 +25.3% | 4 qtrs — |
| 45 | UBS GROUP AG | 147.3K -627.3K (-81.0%) | 708.5K -2.8M (-79.9%) | 0.08% -0.328 pp | 0.00% 0.000 pp | USD4.27 +12.6% | 13 qtrs — |
| 46 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 144.1K +12.6K (+9.6%) | 693.2K +96.3K (+16.1%) | 0.08% +0.007 pp | 0.00% +0.000 pp | USD3.87 +24.3% | 19 qtrs — |
| 47 | ALLIANCEBERNSTEIN L.P. | 143.9K +— (+0.0%) | 692.0K +38.8K (+5.9%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD2.98 +61.4% | 19 qtrs — |
| 48 | BALYASNY ASSET MANAGEMENT L.P. | 141.6K +34.0K (+31.6%) | 681.3K +192.5K (+39.4%) | 0.07% +0.018 pp | 0.00% +0.000 pp | USD4.60 +4.6% | 5 qtrs — |
| 49 | DEUTSCHE BANK AG\ | 140.2K +8.4K (+6.4%) | 674.4K +75.9K (+12.7%) | 0.07% +0.004 pp | 0.00% +0.000 pp | USD3.43 +40.2% | 22 qtrs — |
| 50 | FMR LLC | 136.6K +47.1K (+52.6%) | 656.8K +250.7K (+61.7%) | 0.07% +0.025 pp | 0.00% +0.000 pp | USD3.64 +32.1% | 16 qtrs — |
| 51 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 128.3K +28.0K (+27.9%) | 617.2K +161.7K (+35.5%) | 0.07% +0.015 pp | 0.00% +0.000 pp | USD3.68 +30.7% | 8 qtrs — |
| 52 | WEALTH MANAGEMENT ASSOCIATES, INC. | 127.9K +15.1K (+13.3%) | 615.1K +102.9K (+20.1%) | 0.07% +0.008 pp | 0.21% +0.032 pp | USD3.39 +41.9% | 21 qtrs — |
| 53 | LEGAL & GENERAL GROUP PLC | 122.8K -1.4K (-1.1%) | 590.5K +26.7K (+4.7%) | 0.06% -0.001 pp | 0.00% +0.000 pp | USD3.71 +29.6% | 19 qtrs — |
| 54 | MAN GROUP PLC | 120.8K +41.4K (+52.2%) | 581.1K +220.8K (+61.3%) | 0.06% +0.022 pp | 0.00% +0.000 pp | USD4.16 +15.6% | 3 qtrs — |
| 55 | RAFFERTY ASSET MANAGEMENT, LLC | 117.0K +64.0K (+120.8%) | 562.9K +322.3K (+133.9%) | 0.06% +0.033 pp | 0.00% +0.001 pp | USD4.30 +11.9% | 6 qtrs — |
| 56 | SCHRODER INVESTMENT MANAGEMENT GROUP | 121.3K +— (+0.0%) | 560.5K +19.4K (+3.6%) | 0.06% 0.000 pp | 0.00% +0.000 pp | USD3.09 +55.7% | 3 qtrs — |
| 57 | CAMPBELL & CO INVESTMENT ADVISER LLC | 113.1K +39.8K (+54.3%) | 544.1K +211.4K (+63.5%) | 0.06% +0.021 pp | 0.03% +0.001 pp | USD4.64 +3.7% | 2 qtrs — |
| 58 | CAPTION MANAGEMENT, LLC | 100.0K +100.0K (+100.0%) | 481.0K +481.0K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.003 pp | USD4.81 +0.0% | 1 qtrs NEW |
| 59 | JPMORGAN CHASE & CO | 97.9K -354.0 (-0.4%) | 470.8K +24.8K (+5.6%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD3.41 +41.1% | 20 qtrs — |
| 60 | STATE OF WISCONSIN INVESTMENT BOARD | 92.8K +79.9K (+621.2%) | 446.2K +387.8K (+664.1%) | 0.05% +0.042 pp | 0.00% +0.001 pp | USD4.77 +0.8% | 6 qtrs — |
| 61 | PRICE T ROWE ASSOCIATES INC /MD/ | 89.2K +6.2K (+7.5%) | 430.0K +53.0K (+14.1%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD3.13 +53.7% | 15 qtrs — |
| 62 | SIG BROKERAGE, LP | 81.9K +— (+0.0%) | 393.9K +22.1K (+5.9%) | 0.04% 0.000 pp | 0.01% +0.002 pp | USD4.54 +5.9% | 2 qtrs — |
| 63 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 77.2K +3.4K (+4.5%) | 369.8K +35.0K (+10.4%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD3.34 +44.0% | 7 qtrs — |
| 64 | ENTRYPOINT CAPITAL, LLC | 75.6K +46.7K (+161.9%) | 363.7K +232.6K (+177.5%) | 0.04% +0.024 pp | 0.14% +0.091 pp | USD4.20 +14.5% | 4 qtrs — |
| 65 | EXOME ASSET MANAGEMENT LLC | 75.5K +— (+0.0%) | 363.1K +20.4K (+5.9%) | 0.04% +0.000 pp | 0.17% -0.034 pp | USD3.09 +55.7% | 5 qtrs — |
| 66 | CLEAR HARBOR ASSET MANAGEMENT, LLC | 74.8K +— (+0.0%) | 359.6K +20.2K (+5.9%) | 0.04% +0.000 pp | 0.02% +0.006 pp | USD2.24 +114.7% | 13 qtrs — |
| 67 | METLIFE INVESTMENT MANAGEMENT, LLC | 73.2K -14.6K (-16.6%) | 352.3K -46.6K (-11.7%) | 0.04% -0.008 pp | 0.00% 0.000 pp | USD2.93 +64.2% | 18 qtrs — |
| 68 | INTECH INVESTMENT MANAGEMENT LLC | 70.6K +23.1K (+48.6%) | 339.4K +123.8K (+57.4%) | 0.04% +0.012 pp | 0.00% +0.001 pp | USD4.00 +20.3% | 6 qtrs — |
| 69 | LAZARD ASSET MANAGEMENT LLC | 67.8K +67.8K (+100.0%) | 326.3K +326.3K (+100.0%) | 0.04% +0.035 pp | 0.00% +0.001 pp | USD4.81 +0.0% | 1 qtrs NEW |
| 70 | ROYAL BANK OF CANADA | 65.7K -171.1K (-72.3%) | 316.0K -759.0K (-70.6%) | 0.03% -0.089 pp | 0.00% 0.000 pp | USD3.09 +55.7% | 42 qtrs — |
| 71 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 63.0K +— (+0.0%) | 303.0K +17.0K (+5.9%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD4.54 +5.9% | 6 qtrs — |
| 72 | BNP PARIBAS ARBITRAGE, SNC | 62.8K -27.1K (-30.2%) | 301.9K -106.2K (-26.0%) | 0.03% -0.014 pp | 0.00% 0.000 pp | USD3.25 +48.0% | 19 qtrs — |
| 73 | BOOTHBAY FUND MANAGEMENT, LLC | 61.3K +— (+0.0%) | 294.9K +16.6K (+5.9%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD4.54 +5.9% | 2 qtrs — |
| 74 | JANUS HENDERSON GROUP PLC | 60.9K +— (+0.0%) | 293.2K +16.4K (+5.9%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD3.85 +24.9% | 6 qtrs — |
| 75 | RAYMOND JAMES FINANCIAL INC | 60.2K +60.2K (+100.0%) | 289.5K +289.5K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD4.81 +0.0% | 5 qtrs — |
| 76 | IRENIC CAPITAL MANAGEMENT LP | 59.9K +59.9K (+100.0%) | 287.9K +287.9K (+100.0%) | 0.03% +0.031 pp | 0.02% +0.019 pp | USD4.81 +0.0% | 1 qtrs NEW |
| 77 | GROUP ONE TRADING, L.P. | 58.4K +12.6K (+27.6%) | 281.0K +73.1K (+35.1%) | 0.03% +0.007 pp | 0.00% +0.000 pp | USD4.02 +19.7% | 9 qtrs — |
| 78 | VIRTUS INVESTMENT ADVISERS, INC. | 56.5K +24.7K (+77.7%) | 271.7K +127.4K (+88.3%) | 0.03% +0.013 pp | 0.07% +0.033 pp | USD4.17 +15.3% | 4 qtrs — |
| 79 | QUANTINNO CAPITAL MANAGEMENT LP | 54.7K +18.8K (+52.3%) | 262.9K +100.0K (+61.3%) | 0.03% +0.010 pp | 0.00% +0.000 pp | USD4.63 +3.9% | 2 qtrs — |
| 80 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 54.1K -19.6K (-26.6%) | 257.9K -76.7K (-22.9%) | 0.03% -0.010 pp | 0.00% 0.000 pp | USD3.15 +52.7% | 7 qtrs — |
| 81 | CREATIVE PLANNING | 51.9K +225.0 (+0.4%) | 249.7K +15.0K (+6.4%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD3.00 +60.3% | 9 qtrs — |
| 82 | JANE STREET GROUP, LLC | 51.1K +51.1K (+100.0%) | 245.8K +245.8K (+100.0%) | 0.03% +0.027 pp | 0.00% +0.000 pp | USD4.81 +0.0% | 1 qtrs NEW |
| 83 | ALPHACENTRIC ADVISORS LLC | 47.9K +47.9K (+100.0%) | 230.5K +230.5K (+100.0%) | 0.03% +0.025 pp | 0.23% +0.230 pp | USD4.81 +0.0% | 1 qtrs NEW |
| 84 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 47.5K -6.7K (-12.4%) | 228.3K -17.6K (-7.2%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD2.88 +67.0% | 19 qtrs — |
| 85 | LOS ANGELES CAPITAL MANAGEMENT LLC | 46.5K +46.5K (+100.0%) | 225.2K +225.2K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.001 pp | USD4.81 +0.0% | 3 qtrs — |
| 86 | PROFUND ADVISORS LLC | 45.1K +31.4K (+228.7%) | 217.1K +154.7K (+248.3%) | 0.02% +0.016 pp | 0.01% +0.005 pp | USD4.47 +7.6% | 6 qtrs — |
| 87 | MERCER GLOBAL ADVISORS INC /ADV | 45.1K +6.2K (+15.8%) | 217.0K +40.2K (+22.7%) | 0.02% +0.003 pp | 0.00% +0.000 pp | USD3.51 +37.0% | 5 qtrs — |
| 88 | CITADEL ADVISORS LLC | 44.5K -8.3K (-15.7%) | 214.0K -25.7K (-10.7%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD3.40 +41.5% | 22 qtrs — |
| 89 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 41.7K +— (+0.0%) | 200.4K +11.2K (+5.9%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.63 +32.5% | 5 qtrs — |
| 90 | SG AMERICAS SECURITIES, LLC | 41.6K +18.3K (+78.1%) | 200.0K +94.0K (+88.7%) | 0.02% +0.010 pp | 0.00% 0.000 pp | USD4.19 +14.8% | 18 qtrs — |
| 91 | PREMIER PATH WEALTH PARTNERS, LLC | 40.0K +— (+0.0%) | 192.4K +10.8K (+5.9%) | 0.02% +0.000 pp | 0.02% +0.002 pp | USD2.73 +76.2% | 9 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 89 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.69% | 399.2K | 0.65% |
| 2 | Janus Henderson Small Cap Growth Alpha ETF JSML | 0.66% | 2.45M | 0.30% |
| 3 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.53% | 115.5K | 0.20% |
| 4 | iShares Micro-Cap ETF IWC | 0.17% | 2.59M | 0.60% |
| 5 | Global X - S&P Biotech ETF CURE.AX | 0.16% | 58.9K | 0.45% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.16% | 17.69M | 0.35% |
| 7 | iShares MSCI USA Small-Cap Min Vol Factor ETF SMMV | 0.10% | 300.8K | 0.20% |
| 8 | State Street SPDR S&P Kensho New Economies Composite ETF KOMP | 0.09% | 2.57M | 0.20% |
| 9 | State Street SPDR US Small Cap Low Volatility Index ETF SMLV | 0.09% | 217.3K | 0.12% |
| 10 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.07% | 709.2K | 0.20% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
361.6K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+361,600
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | Nguyen Tuan | Officer | A-Award | A | Stock Option (Right to Buy) | 188,400 | 4.39 | 827.1K | 188,400 | D | ↗ |
| 2026-02-02 | Androski Lindsay | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 71,700 | 4.39 | 314.8K | 71,700 | D | ↗ |
| 2025-08-04 | Sawhney Roger | Director | A-Award | A | Stock Option (Right to Buy) | 157,600 | 3.34 | 526.4K | 157,600 | D | ↗ |
| 2025-03-31 | Nguyen Tuan | Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 3.49 | 2.62M | 750,000 | D | ↗ |
| 2025-03-28 | Nguyen Tuan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-18 | Hasija Anuj | Director | A-Award | A | Stock Option (Right to Buy) | 157,600 | 3.20 | 504.3K | 157,600 | D | ↗ |
| 2025-03-18 | Beardsley Robert A | Director | A-Award | A | Stock Option (Right to Buy) | 157,600 | 3.20 | 504.3K | 157,600 | D | ↗ |
| 2025-03-18 | Androski Lindsay | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 310,422 | 3.20 | 993.4K | 310,422 | D | ↗ |
| 2025-02-24 | Hasija Anuj | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-24 | Gline Matthew | Director / 10% Owner | — | — | Common Shares | 0 | 0.00 | — | 38,847,462 | I | ↗ |
| 2025-02-24 | Bishop Joseph E | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-24 | Beardsley Robert A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-24 | Androski Lindsay | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-14 | Sims Karen | Officer | A-Award | A | Common Shares | 49,300 | 0.00 | — | 155,494 | D | ↗ |
| 2025-02-14 | Naftzger J. Christopher | Officer | A-Award | A | Common Shares | 54,300 | 0.00 | — | 140,544 | D | ↗ |
| 2025-02-14 | McElhaugh Michael J. | Director / Officer | A-Award | A | Common Shares | 177,000 | 0.00 | — | 1,658,003 | D | ↗ |
| 2025-02-14 | HASTINGS DAVID C | Officer | A-Award | A | Stock Option (Right to Buy) | 365,800 | 3.29 | 1.20M | 365,800 | D | ↗ |
| 2025-02-04 | Sims Karen | Officer | S-Sale | D | Common Shares | 19,348 | 3.28 | 63.5K | 106,194 | D | ↗ |
| 2025-02-04 | Naftzger J. Christopher | Officer | S-Sale | D | Common Shares | 11,333 | 3.28 | 37.2K | 86,244 | D | ↗ |
| 2025-02-04 | McElhaugh Michael J. | Director / Officer | S-Sale | D | Common Shares | 23,790 | 3.28 | 78.1K | 1,481,003 | D | ↗ |
| 2025-02-04 | HASTINGS DAVID C | Officer | S-Sale | D | Common Shares | 22,183 | 3.28 | 72.8K | 159,724 | D | ↗ |
| 2024-08-14 | MANCHESTER KEITH S | Director | M-Exempt | D | Stock Option (Right to Buy) | 54,915 | 0.56 | 30.8K | 0 | — | ↗ |
| 2024-05-23 | Torti Frank | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 3.28 | 219.8K | 67,000 | — | ↗ |
| 2024-05-23 | Rewolinski Melissa | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 3.28 | 219.8K | 67,000 | — | ↗ |
| 2024-05-23 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 3.28 | 219.8K | 67,000 | — | ↗ |
| 2024-05-23 | MANCHESTER KEITH S | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 3.28 | 219.8K | 67,000 | — | ↗ |
| 2024-05-23 | HENRIQUES RICHARD C JR | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 3.28 | 219.8K | 67,000 | — | ↗ |
| 2024-05-23 | BURGESS DANIEL D | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 3.28 | 219.8K | 67,000 | — | ↗ |
| 2024-02-02 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 9,982 | 2.31 | 23.1K | 1,485,121 | — | ↗ |
| 2024-02-02 | Sims Karen | Officer | S-Sale | D | Common Shares | 4,358 | 2.31 | 10.1K | 125,542 | — | ↗ |
| 2024-02-02 | McElhaugh Michael J. | Director / Officer | S-Sale | D | Common Shares | 10,164 | 2.31 | 23.5K | 1,504,793 | — | ↗ |
| 2024-02-02 | HASTINGS DAVID C | Officer | S-Sale | D | Common Shares | 9,593 | 2.31 | 22.2K | 181,907 | — | ↗ |
| 2024-02-01 | Sofia Michael J. | Officer | A-Award | A | Stock Option (Right to Buy) | 437,800 | 2.40 | 1.05M | 437,800 | — | ↗ |
| 2024-02-01 | Sims Karen | Officer | A-Award | A | Common Shares | 101,000 | 0.00 | — | 129,900 | — | ↗ |
| 2024-02-01 | Naftzger J. Christopher | Officer | A-Award | A | Common Shares | 95,100 | 0.00 | — | 95,100 | — | ↗ |
| 2024-02-01 | McElhaugh Michael J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 495,100 | 2.40 | 1.19M | 495,100 | — | ↗ |
| 2024-02-01 | HASTINGS DAVID C | Officer | A-Award | A | Common Shares | 112,500 | 0.00 | — | 191,500 | — | ↗ |
| 2023-07-12 | Rewolinski Melissa | Director | A-Award | A | Stock Option (Right to Buy) | 110,000 | 2.27 | 249.7K | 110,000 | — | ↗ |
| 2023-07-10 | Sims Karen | Officer | — | D | Stock Option (Right to Buy) | 25,500 | 5.20 | 132.6K | 0 | — | ↗ |
| 2023-07-10 | Naftzger J. Christopher | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-24 | Torti Frank | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.56 | 140.8K | 55,000 | — | ↗ |
| 2023-05-24 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.56 | 140.8K | 55,000 | — | ↗ |
| 2023-05-24 | MANCHESTER KEITH S | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.56 | 140.8K | 55,000 | — | ↗ |
| 2023-05-24 | HENRIQUES RICHARD C JR | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.56 | 140.8K | 55,000 | — | ↗ |
| 2023-05-24 | BURGESS DANIEL D | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.56 | 140.8K | 55,000 | — | ↗ |
| 2023-02-01 | Sofia Michael J. | Officer | A-Award | A | Stock Option (Right to Buy) | 328,700 | 2.90 | 953.2K | 328,700 | — | ↗ |
| 2023-02-01 | McElhaugh Michael J. | Officer | A-Award | A | Stock Option (Right to Buy) | 334,700 | 2.90 | 970.6K | 334,700 | — | ↗ |
| 2023-02-01 | Howard Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 278,700 | 2.90 | 808.2K | 278,700 | — | ↗ |
| 2023-02-01 | HASTINGS DAVID C | Officer | A-Award | A | Stock Option (Right to Buy) | 316,000 | 2.90 | 916.4K | 316,000 | — | ↗ |
| 2023-02-01 | Collier William H. | Director / Officer | A-Award | A | Common Shares | 216,500 | 0.00 | — | 216,500 | — | ↗ |
| 2022-05-25 | Tran Tram | Director | A-Award | A | Stock Option (Right to Buy) | 41,000 | 0.00 | — | 41,000 | — | ↗ |
| 2022-05-25 | Torti Frank | Director | A-Award | A | Stock Option (Right to Buy) | 41,000 | 2.25 | 92.3K | 41,000 | — | ↗ |
| 2022-05-25 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 41,000 | 0.00 | — | 41,000 | — | ↗ |
| 2022-05-25 | MANCHESTER KEITH S | Director | A-Award | A | Stock Option (Right to Buy) | 41,000 | 0.00 | — | 41,000 | — | ↗ |
| 2022-05-25 | HENRIQUES RICHARD C JR | Director | A-Award | A | Stock Option (Right to Buy) | 41,000 | 0.00 | — | 41,000 | — | ↗ |
| 2022-05-25 | BURGESS DANIEL D | Director | A-Award | A | Stock Option (Right to Buy) | 41,000 | 2.25 | 92.3K | 41,000 | — | ↗ |
| 2022-01-20 | Sofia Michael J. | Officer | A-Award | A | Stock Option (Right to Buy) | 285,000 | 2.81 | 800.9K | 285,000 | — | ↗ |
| 2022-01-20 | Picchio Gaston | Officer | A-Award | A | Stock Option (Right to Buy) | 256,500 | 2.81 | 720.8K | 256,500 | — | ↗ |
| 2022-01-20 | McElhaugh Michael J. | Officer | A-Award | A | Stock Option (Right to Buy) | 325,850 | 2.81 | 915.6K | 325,850 | — | ↗ |
| 2022-01-20 | Howard Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 237,500 | 2.81 | 667.4K | 237,500 | — | ↗ |
| 2022-01-20 | HASTINGS DAVID C | Officer | A-Award | A | Stock Option (Right to Buy) | 285,000 | 2.81 | 800.9K | 285,000 | — | ↗ |
| 2022-01-20 | Collier William H. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 787,550 | 2.81 | 2.21M | 787,550 | — | ↗ |
| 2021-12-01 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 200,000 | 5.09 | 1.02M | 1,303,403 | — | ↗ |
| 2021-11-09 | Tran Tram | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 3.50 | 154.0K | 44,000 | — | ↗ |
| 2021-10-18 | Roivant Sciences Ltd. | 10% Owner | C-Conversion | A | Common shares, without par value | 22,833,922 | 0.00 | — | 38,847,462 | — | ↗ |
| 2021-06-03 | Torti Frank | Director | A-Award | A | Stock Options | 22,000 | 2.95 | 64.9K | 22,000 | — | ↗ |
| 2021-06-03 | Meyers James R | Director | A-Award | A | Stock Options | 22,000 | 2.95 | 64.9K | 22,000 | — | ↗ |
| 2021-06-03 | MANCHESTER KEITH S | Director | A-Award | A | Stock Options | 22,000 | 2.95 | 64.9K | 22,000 | — | ↗ |
| 2021-06-03 | HENRIQUES RICHARD C JR | Director | A-Award | A | Stock Options | 22,000 | 2.95 | 64.9K | 22,000 | — | ↗ |
| 2021-06-03 | Cheng Andrew | Director | A-Award | A | Stock Options | 22,000 | 2.95 | 64.9K | 22,000 | — | ↗ |
| 2021-06-03 | BURGESS DANIEL D | Director | A-Award | A | Stock Options | 22,000 | 2.95 | 64.9K | 22,000 | — | ↗ |
| 2021-02-13 | Sofia Michael J. | Officer | A-Award | A | Stock Options | 290,000 | 4.33 | 1.26M | 290,000 | — | ↗ |
| 2021-02-13 | Picchio Gaston | Officer | A-Award | A | Stock Options | 250,000 | 4.33 | 1.08M | 250,000 | — | ↗ |
| 2021-02-13 | McElhaugh Michael J. | Officer | A-Award | A | Stock Options | 249,000 | 4.33 | 1.08M | 249,000 | — | ↗ |
| 2021-02-13 | Howard Elizabeth | Officer | A-Award | A | Stock Options | 200,000 | 4.33 | 866.0K | 200,000 | — | ↗ |
| 2021-02-13 | HASTINGS DAVID C | Officer | A-Award | A | Stock Options | 250,000 | 4.33 | 1.08M | 250,000 | — | ↗ |
| 2021-02-13 | Collier William H. | Director / Officer | A-Award | A | Stock Options | 675,000 | 4.33 | 2.92M | 675,000 | — | ↗ |
| 2021-02-09 | McElhaugh Michael J. | Officer | S-Sale | D | Common Stock | 20,000 | 5.00 | 100.0K | 1,307,457 | — | ↗ |
| 2020-12-14 | McElhaugh Michael J. | Officer | S-Sale | D | Common Stock | 30,000 | 5.00 | 150.0K | 1,337,457 | — | ↗ |
| 2020-09-23 | Picchio Gaston | Officer | A-Award | A | Common Stock | 50,000 | 3.35 | 167.5K | 50,000 | — | ↗ |
| 2020-09-23 | Collier William H. | Director / Officer | A-Award | A | Stock Options | 70,000 | 3.35 | 234.5K | 70,000 | — | ↗ |
| 2020-07-23 | McElhaugh Michael J. | Officer | S-Sale | D | Common Stock | 20,000 | 5.01 | 100.2K | 1,367,457 | — | ↗ |
| 2020-05-28 | Torti Frank | Director | A-Award | A | Stock Options | 22,000 | 2.16 | 47.5K | 22,000 | — | ↗ |
| 2020-05-28 | Meyers James R | Director | A-Award | A | Stock Options | 22,000 | 2.16 | 47.5K | 22,000 | — | ↗ |
| 2020-05-28 | MANCHESTER KEITH S | Director | A-Award | A | Stock Options | 22,000 | 2.16 | 47.5K | 22,000 | — | ↗ |
| 2020-05-28 | HENRIQUES RICHARD C JR | Director | A-Award | A | Stock Options | 22,000 | 2.16 | 47.5K | 22,000 | — | ↗ |
| 2020-05-28 | Collier William H. | Director / Officer | A-Award | A | Stock Options | 262,313 | 3.35 | 878.7K | 262,313 | — | ↗ |
| 2020-05-28 | Cheng Andrew | Director | A-Award | A | Stock Options | 22,000 | 2.16 | 47.5K | 22,000 | — | ↗ |
| 2020-05-28 | BURGESS DANIEL D | Director | A-Award | A | Stock Options | 22,000 | 2.16 | 47.5K | 22,000 | — | ↗ |
| 2020-02-18 | Venker Eric | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-17 | Sofia Michael J. | Officer | A-Award | A | Stock Options | 250,000 | 3.35 | 837.5K | 250,000 | — | ↗ |
| 2020-02-17 | Picchio Gaston | Officer | A-Award | A | Stock Options | 150,000 | 3.35 | 502.5K | 150,000 | — | ↗ |
| 2020-02-17 | McElhaugh Michael J. | Officer | A-Award | A | Stock Options | 200,000 | 3.35 | 670.0K | 200,000 | — | ↗ |
| 2020-02-17 | Howard Elizabeth | Officer | A-Award | A | Stock Options | 79,500 | 3.35 | 266.3K | 79,500 | — | ↗ |
| 2020-02-17 | HASTINGS DAVID C | Officer | A-Award | A | Stock Options | 100,000 | 3.35 | 335.0K | 100,000 | — | ↗ |
| 2020-02-17 | Collier William H. | Director / Officer | A-Award | A | Stock Options | 367,087 | 3.35 | 1.23M | 367,087 | — | ↗ |
| 2019-08-17 | Torti Frank | Director | A-Award | A | Stock Options | 22,000 | 1.50 | 33.0K | 22,000 | — | ↗ |
| 2019-08-17 | POTTER MYRTLE S | Director | A-Award | A | Stock Options | 22,000 | 1.50 | 33.0K | 22,000 | — | ↗ |
| 2019-08-17 | Meyers James R | Director | A-Award | A | Stock Options | 22,000 | 1.50 | 33.0K | 22,000 | — | ↗ |
| 2019-08-17 | MANCHESTER KEITH S | Director | A-Award | A | Stock Options | 22,000 | 1.50 | 33.0K | 22,000 | — | ↗ |
| 2019-08-17 | HENRIQUES RICHARD C JR | Director | A-Award | A | Stock Options | 22,000 | 1.50 | 33.0K | 22,000 | — | ↗ |
| 2019-08-17 | Cheng Andrew | Director | A-Award | A | Stock Options | 60,000 | 1.50 | 90.0K | 60,000 | — | ↗ |
| 2019-08-17 | BURGESS DANIEL D | Director | A-Award | A | Stock Options | 22,000 | 1.50 | 33.0K | 22,000 | — | ↗ |
| 2019-07-10 | VIKING GLOBAL PERFORMANCE LLC | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-10 | VIKING GLOBAL INVESTORS LP | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-10 | SVF Investments (UK) Ltd | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-10 | QVT Associates GP LLC | Director / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-10 | Machado Patrick | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-10 | Lo Andrew | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-10 | Dexxon Holdings Ltd. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-24 | Collier William H. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,112,000 | 2.18 | 2.42M | 1,112,000 | — | ↗ |
| 2019-03-01 | Sofia Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 145,000 | 4.57 | 662.7K | 145,000 | — | ↗ |
| 2019-03-01 | Picchio Gaston | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 137,500 | 4.57 | 628.4K | 137,500 | — | ↗ |
| 2019-03-01 | Murray Mark J. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 357,500 | 4.57 | 1.63M | 357,500 | — | ↗ |
| 2019-03-01 | McElhaugh Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 104,500 | 4.57 | 477.6K | 104,500 | — | ↗ |
| 2019-03-01 | Howard Elizabeth | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 137,500 | 4.57 | 628.4K | 137,500 | — | ↗ |
| 2019-03-01 | HASTINGS DAVID C | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 137,500 | 4.57 | 628.4K | 137,500 | — | ↗ |
| 2019-01-01 | Viking Global Equities Master Ltd. | 10% Owner | — | I | Common Shares | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2018-12-11 | VandenEnden Koert | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 7,500 | 4.44 | 33.3K | 7,500 | — | ↗ |
| 2018-12-11 | McElhaugh Michael J. | Officer | — | D | Common Shares | 0 | 0.00 | — | 1,387,457 | — | ↗ |
| 2018-11-28 | Murray Mark J. | Director | M-Exempt | A | Common Shares | 25,000 | 1.35 | 33.8K | 341,396 | — | ↗ |
| 2018-11-26 | Torti Frank | Director | A-Award | A | Director Share Option (right to buy) | 44,000 | 4.72 | 207.7K | 44,000 | — | ↗ |
| 2018-10-18 | POTTER MYRTLE S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | Meyers James R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-10-08 | Picchio Gaston | Officer | A-Award | A | Employee Share Option (Right to Buy) | 200,000 | 9.38 | 1.88M | 200,000 | — | ↗ |
| 2018-08-13 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 4,250 | 9.51 | 40.4K | 167,162 | — | ↗ |
| 2018-07-11 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 10,000 | 10.00 | 100.0K | 1,503,403 | — | ↗ |
| 2018-07-09 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 10,000 | 8.91 | 89.1K | 1,513,403 | — | ↗ |
| 2018-07-06 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 10,000 | 8.45 | 84.5K | 1,523,403 | — | ↗ |
| 2018-07-05 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 10,000 | 8.40 | 84.0K | 1,533,403 | — | ↗ |
| 2018-07-03 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 10,000 | 8.00 | 80.0K | 1,543,403 | — | ↗ |
| 2018-06-19 | Ramaswamy Vivek | Director | A-Award | A | Director Stock Option (Right to Buy) | 22,000 | 6.75 | 148.5K | 22,000 | — | ↗ |
| 2018-06-19 | MANCHESTER KEITH S | Director | A-Award | A | Director Stock Option (Right to Buy) | 22,000 | 6.75 | 148.5K | 22,000 | — | ↗ |
| 2018-06-19 | HENRIQUES RICHARD C JR | Director | A-Award | A | Director Stock Option (Right to Buy) | 22,000 | 6.75 | 148.5K | 22,000 | — | ↗ |
| 2018-06-19 | HASTINGS DAVID C | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 6.75 | 1.35M | 200,000 | — | ↗ |
| 2018-06-19 | CONRAD HERBERT J | Director | A-Award | A | Director Stock Option (Right to Buy) | 22,000 | 6.75 | 148.5K | 22,000 | — | ↗ |
| 2018-06-19 | BURGESS DANIEL D | Director | A-Award | A | Director Stock Option (Right to Buy) | 22,000 | 6.75 | 148.5K | 22,000 | — | ↗ |
| 2018-06-11 | HASTINGS DAVID C | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-04-17 | Murray Mark J. | Director / Officer | M-Exempt | A | Common Shares | 27,007 | 0.35 | 9.6K | 316,396 | — | ↗ |
| 2018-04-16 | VandenEnden Koert | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 5.20 | 130.0K | 25,000 | — | ↗ |
| 2018-04-16 | Symonds William T. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 30,000 | 5.20 | 156.0K | 30,000 | — | ↗ |
| 2018-04-16 | Sofia Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 160,000 | 5.20 | 832.0K | 160,000 | — | ↗ |
| 2018-04-16 | Murray Mark J. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 418,187 | 5.20 | 2.17M | 418,187 | — | ↗ |
| 2018-04-16 | Howard Elizabeth | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 5.20 | 780.0K | 150,000 | — | ↗ |
| 2018-04-11 | Lutwyche Peter | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-02-16 | VandenEnden Koert | Officer | — | D | Common Shares | 0 | 0.00 | — | 2,750 | — | ↗ |
| 2018-02-16 | Cousins Bruce | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-12 | VIKING GLOBAL PERFORMANCE LLC | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 664,000 | 7.13 | 4.73M | 1,164,000 | — | ↗ |
| 2018-01-12 | VIKING GLOBAL INVESTORS LP | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 664,000 | 7.13 | 4.73M | 1,164,000 | — | ↗ |
| 2018-01-12 | SVF Investments (UK) Ltd | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 664,000 | 7.13 | 4.73M | 1,164,000 | — | ↗ |
| 2018-01-12 | Roivant Sciences Ltd. | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 664,000 | 7.13 | 4.73M | 1,164,000 | — | ↗ |
| 2018-01-12 | QVT Associates GP LLC | Director / 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 664,000 | 7.13 | 4.73M | 1,164,000 | — | ↗ |
| 2018-01-12 | Machado Patrick | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 664,000 | 7.13 | 4.73M | 1,164,000 | — | ↗ |
| 2018-01-12 | Lo Andrew | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 664,000 | 7.13 | 4.73M | 1,164,000 | — | ↗ |
| 2018-01-12 | Dexxon Holdings Ltd. | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 664,000 | 7.13 | 4.73M | 1,164,000 | — | ↗ |
| 2017-10-16 | VIKING GLOBAL PERFORMANCE LLC | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2017-10-16 | VIKING GLOBAL INVESTORS LP | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2017-10-16 | SVF Investments (UK) Ltd | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2017-10-16 | Roivant Sciences Ltd. | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2017-10-16 | QVT Associates GP LLC | Director / 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2017-10-16 | Machado Patrick | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2017-10-16 | Lo Andrew | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2017-10-16 | Dexxon Holdings Ltd. | 10% Owner | P-Purchase | A | Series A Participating Convertible Preferred Shares | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2017-10-03 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 10,000 | 8.00 | 80.0K | 1,553,403 | — | ↗ |
| 2017-09-06 | SVF Investments (UK) Ltd | 10% Owner | — | I | Common Shares | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2017-09-06 | Dexcel Pharma Technologies Ltd. | 10% Owner | — | I | Common Shares, no par value | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2017-08-15 | Sofia Michael J. | Officer | S-Sale | D | Common Shares | 10,000 | 3.75 | 37.5K | 191,412 | — | ↗ |
| 2017-07-01 | Shabet Rose Sharon | 10% Owner | — | I | Common Shares | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2017-06-21 | Ramaswamy Vivek | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 3.55 | 78.1K | 22,000 | — | ↗ |
| 2017-06-21 | MANCHESTER KEITH S | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 3.55 | 78.1K | 22,000 | — | ↗ |
| 2017-06-21 | KARBE FRANK | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 3.55 | 78.1K | 22,000 | — | ↗ |
| 2017-06-21 | HENRIQUES RICHARD C JR | Director | A-Award | A | Director Stock Option Grant (Right to Buy) | 22,000 | 3.55 | 78.1K | 22,000 | — | ↗ |
| 2017-06-21 | CONRAD HERBERT J | Director | A-Award | A | Director Stock Option Grant (Right to Buy) | 22,000 | 3.55 | 78.1K | 22,000 | — | ↗ |
| 2017-06-21 | BURGESS DANIEL D | Director | A-Award | A | Director Stock Option Grant (Right to Buy) | 22,000 | 3.55 | 78.1K | 22,000 | — | ↗ |
| 2017-03-24 | VandenEnden Koert | Officer | — | D | Stock Options (Right to Buy) | 15,000 | 3.15 | 47.3K | 0 | — | ↗ |
| 2017-03-24 | Symonds William T. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,000 | 3.15 | 157.5K | 50,000 | — | ↗ |
| 2017-03-24 | Sofia Michael J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 3.15 | 472.5K | 150,000 | — | ↗ |
| 2017-03-24 | Murray Mark J. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 450,000 | 3.15 | 1.42M | 450,000 | — | ↗ |
| 2017-03-24 | Lutwyche Peter | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 3.15 | 393.8K | 125,000 | — | ↗ |
| 2017-03-24 | Howard Elizabeth | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 3.15 | 393.8K | 125,000 | — | ↗ |
| 2017-03-24 | Cousins Bruce | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 3.15 | 630.0K | 200,000 | — | ↗ |
| 2017-03-24 | BURGESS DANIEL D | Director | A-Award | A | Director Stock Option (Right to Buy) | 50,000 | 3.15 | 157.5K | 50,000 | — | ↗ |
| 2017-03-23 | BURGESS DANIEL D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-07 | VandenEnden Koert | Officer | — | D | Stock Options (Right to Buy) | 35,000 | 3.05 | 106.8K | 0 | — | ↗ |
| 2016-10-18 | Machado Patrick | 10% Owner | — | I | Common Shares, no par value | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2016-09-30 | Kowalski Mark | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-09-30 | Abrams Michael J. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-08-16 | Abrams Michael J. | Director / Officer | M-Exempt | A | Common Shares | 14,178 | 0.35 | 4.9K | 42,097 | — | ↗ |
| 2016-07-08 | VIKING GLOBAL PERFORMANCE LLC | 10% Owner | — | I | Common Shares | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2016-07-08 | VIKING GLOBAL INVESTORS LP | 10% Owner | — | I | Common Shares | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2016-07-08 | QVT Associates GP LLC | Director / 10% Owner | — | I | Common shares, no par value ("Common Shares") | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2016-07-08 | Lo Andrew | 10% Owner | — | I | Common Shares, no par value | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2016-07-08 | Dexxon Holdings Ltd. | 10% Owner | — | I | Common Shares, no par value | 0 | 0.00 | — | 16,013,540 | — | ↗ |
| 2016-06-16 | Murray Mark J. | Director / Officer | X-InTheMoney | D | Warrants | 5,000 | 2.57 | 12.8K | 0 | — | ↗ |
| 2016-06-03 | Ramaswamy Vivek | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 7,500 | 3.99 | 29.9K | 7,500 | — | ↗ |
| 2016-06-03 | MANCHESTER KEITH S | Director | A-Award | A | Stock Option (right to buy) | 7,500 | 3.99 | 29.9K | 7,500 | — | ↗ |
| 2016-06-03 | KARBE FRANK | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,500 | 3.99 | 29.9K | 7,500 | — | ↗ |
| 2016-06-03 | HENRIQUES RICHARD C JR | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,500 | 3.99 | 29.9K | 7,500 | — | ↗ |
| 2016-06-03 | CONRAD HERBERT J | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,500 | 3.99 | 29.9K | 7,500 | — | ↗ |
| 2016-04-30 | Higgins Patrick T. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-1.42M
Shares Outstanding
196.94M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael McElhaugh Former Interim President and Chief Executive Officer | 109.7K | — | 582.3K | 1.86M | — | 1.03M | 3.58M | 68.13% | ↗ |
| 2 | 2025 | Tuan Nguyen Chief Financial Officer | 359.8K | — | — | 1.88M | 159.8K | 17.5K | 2.42M | 77.78% | ↗ |
| 3 | 2025 | David C. Hastings Former Chief Financial Officer | 138.6K | — | 296.4K | 944.3K | — | 839.1K | 2.22M | 55.93% | ↗ |
| 4 | 2025 | Lindsay Androski President and Chief Executive Officer | 437.8K | — | — | 714.8K | 216.5K | — | 1.37M | 52.21% | ↗ |
| 5 | 2024 | Michael McElhaugh Former Interim President and Chief Executive Officer | 642.5K | — | 297.1K | 921.5K | 231.8K | 17.3K | 2.11M | 57.75% | ↗ |
| 6 | 2024 | David C. Hastings Former Chief Financial Officer | 502.0K | — | 270.0K | 837.5K | 200.8K | 15.5K | 1.83M | 60.66% | ↗ |
| 7 | 2024 | Michael J. Sofia, Ph.D. Former Chief Scientific Officer | 512.0K | — | 262.8K | 814.8K | 204.8K | 25.6K | 1.82M | 59.21% | ↗ |
| 8 | 2024 | Karen Sims, M.D., Ph.D. Former Chief Medical Officer | 490.0K | — | 242.4K | 751.7K | 196.0K | 17.3K | 1.70M | 58.57% | ↗ |
| 9 | 2023 | William H. Collier Former President and Chief Executive Officer | 637.1K | — | 627.9K | 1.90M | — | 223.6K | 3.39M | 74.58% | ↗ |
| 10 | 2023 | Elizabeth Howard, Ph.D. Former Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | 227.4K | — | 202.1K | 610.7K | — | 802.5K | 1.84M | 44.11% | ↗ |
| 11 | 2023 | Michael McElhaugh Current Interim President and Chief Executive Officer | 483.0K | — | 242.7K | 733.4K | 144.9K | 16.5K | 1.62M | 60.23% | ↗ |
| 12 | 2023 | Michael McElhaugh Former Interim President and Chief Executive Officer | 483.0K | — | 242.7K | 733.4K | 144.9K | 16.5K | 1.62M | 60.23% | ↗ |
| 13 | 2023 | Michael J. Sofia, Ph.D. Chief Scientific Officer | 492.0K | — | 238.4K | 720.2K | 147.6K | 16.5K | 1.61M | 59.37% | ↗ |
| 14 | 2023 | Michael J. Sofia, Ph.D. Former Chief Scientific Officer | 492.0K | — | 238.4K | 720.2K | 147.6K | 16.5K | 1.61M | 59.37% | ↗ |
| 15 | 2023 | David C. Hastings Former Chief Financial Officer | 477.0K | — | 229.1K | 692.4K | 143.1K | 15.2K | 1.56M | 59.19% | ↗ |
| 16 | 2022 | William H. Collier Former President and Chief Executive Officer | 606.8K | — | — | 1.71M | 315.5K | 10.7K | 2.65M | 64.73% | ↗ |
| 17 | 2022 | William H. Collier President and Chief Executive Officer | 606.8K | — | — | 1.71M | 315.5K | 10.7K | 2.65M | 64.73% | ↗ |
| 18 | 2022 | Michael McElhaugh Current Interim President and Chief Executive Officer | 448.8K | — | — | 708.6K | 147.2K | 10.7K | 1.32M | 53.88% | ↗ |
| 19 | 2022 | Michael J. McElhaugh Chief Operating Officer | 448.8K | — | — | 708.6K | 147.2K | 10.7K | 1.32M | 53.88% | ↗ |
| 20 | 2022 | Michael J. Sofia, Ph.D. Chief Scientific Officer | 468.0K | — | — | 619.8K | 149.8K | 10.7K | 1.25M | 49.65% | ↗ |
| 21 | 2021 | William H. Collier President and Chief Executive Officer | 583.5K | — | — | 2.19M | 436.2K | 10.2K | 3.22M | 67.97% | ↗ |
| 22 | 2021 | Michael J. Sofia, Ph.D. Chief Scientific Officer | 452.1K | — | — | 938.9K | 208.0K | 10.2K | 1.61M | 58.35% | ↗ |
| 23 | 2021 | David C. Hastings Chief Financial Officer | 437.1K | — | — | 809.4K | 201.1K | 8.9K | 1.46M | 55.57% | ↗ |
| 24 | 2020 | William H. Collier President and Chief Executive Officer | 566.5K | — | — | 1.76M | 395.8K | 10.0K | 2.73M | 64.36% | ↗ |
| 25 | 2020 | Michael J. Sofia, Ph.D. Chief Scientific Officer | 439.0K | — | — | 605.5K | 188.8K | 10.0K | 1.24M | 48.70% | ↗ |
| 26 | 2020 | Michael J. McElhaugh Chief Business Officer | 415.0K | — | — | 484.4K | 178.5K | 10.0K | 1.09M | 44.53% | ↗ |
| 27 | 2019 | Mark J. Murray, Ph.D. Former President and Chief Executive Officer | 273.5K | — | — | 1.19M | — | 2.31M | 3.78M | 31.58% | ↗ |
| 28 | 2019 | William H. Collier President and Chief Executive Officer | 285.6K | 100.0K | — | 1.79M | 150.9K | 5.6K | 2.33M | 76.77% | ↗ |
| 29 | 2019 | Michael J. Sofia, Ph.D. Chief Scientific Officer | 422.3K | — | — | 484.2K | 135.1K | 9.8K | 1.05M | 46.05% | ↗ |
| 30 | 2019 | David C. Hastings Chief Financial Officer | 412.0K | — | — | 459.1K | 131.8K | 7.3K | 1.01M | 45.45% | ↗ |
| 31 | 2018 | Mark J. Murray, Ph.D. President and Chief Executive Officer | 556.0K | — | — | 1.61M | 306.0K | 55.9K | 2.53M | 63.69% | ↗ |
| 32 | 2018 | Mark J. Murray, Ph.D. Former President and Chief Executive Officer | 556.0K | — | — | 1.61M | 306.0K | 55.9K | 2.53M | 63.69% | ↗ |
| 33 | 2018 | Gaston Picchio, PhD. Chief Development Officer | 87.0K | — | — | 1.38M | 32.0K | — | 1.50M | 92.04% | ↗ |
| 34 | 2018 | David C. Hastings Chief Financial Officer | 224.0K | 75.0K | — | 1.00M | 147.2K | 4.7K | 1.45M | 68.97% | ↗ |
| 35 | 2017 | Dr. Mark Murray President and Chief Executive Officer | 540.0K | 324.0K | — | 1.00M | — | 47.8K | 1.92M | 52.39% | ↗ |
| 36 | 2017 | Mark J. Murray, Ph.D. President and Chief Executive Officer | 540.0K | — | — | 1.00M | 324.0K | 47.8K | 1.92M | 52.39% | ↗ |
| 37 | 2017 | Mr. Bruce Cousins Executive VP and Chief Financial Officer | 350.0K | 115.0K | — | 446.0K | — | 35.5K | 946.5K | 47.12% | ↗ |
| 38 | 2017 | Dr. Michael Sofia Chief Scientific Officer | 350.0K | 150.0K | — | 334.5K | — | 12.3K | 846.8K | 39.50% | ↗ |
| 39 | 2017 | Dr. Elizabeth Howard Executive VP and General Counsel | 330.0K | 123.0K | — | 278.8K | — | 8.3K | 740.1K | 37.67% | ↗ |
| 40 | 2017 | Dr. Peter Lutwyche Chief Technology Officer | 300.0K | 112.0K | — | 278.8K | — | 13.0K | 703.8K | 39.61% | ↗ |
| 41 | 2016 | Dr. Mark Murray President and Chief Executive Officer | 540.0K | 243.0K | — | 1.31M | — | 24.8K | 2.11M | 61.79% | ↗ |
| 42 | 2016 | Dr. Mark Kowalski Former Chief Medical Officer | 378.3K | — | — | 246.7K | — | 640.0K | 1.27M | 19.50% | ↗ |
| 43 | 2016 | Mr. Patrick Higgins Former Chief Business and Commercial Operations Officer | 174.6K | — | — | — | — | 784.0K | 958.5K | 0.00% | ↗ |
| 44 | 2016 | Mr. Bruce Cousins Executive VP and Chief Financial Officer | 350.0K | 105.0K | — | 420.9K | — | 35.3K | 911.2K | 46.19% | ↗ |
| 45 | 2016 | Dr. Michael Sofia Chief Scientific Officer | 350.0K | 105.0K | — | 290.3K | — | 9.0K | 754.3K | 38.48% | ↗ |
| 46 | 2016 | Dr. Elizabeth Howard Executive VP and General Counsel | 275.0K | 85.0K | — | 348.3K | — | 3.3K | 711.6K | 48.95% | ↗ |
| 47 | 2016 | Dr. Peter Lutwyche Chief Technology Officer | 300.0K | 90.0K | — | 174.2K | — | 10.2K | 574.4K | 30.32% | ↗ |
| 48 | 2015 | Dr. Mark Murray President and Chief Executive Officer | 524.9K | 430.0K | — | 3.62M | — | 45.3K | 4.62M | 78.33% | ↗ |
| 49 | 2015 | Dr. Mark Murray President and CEO | 524.9K | 430.0K | — | 3.62M | — | 45.3K | 4.62M | 78.33% | ↗ |
| 50 | 2015 | Mr. Bruce Cousins EVP and CFO | 337.0K | 195.5K | — | 2.00M | — | 37.8K | 2.57M | 77.80% | ↗ |
| 51 | 2015 | Mr. Bruce Cousins Executive VP and Chief Financial Officer | 337.0K | 195.5K | — | 2.00M | — | 37.8K | 2.57M | 77.80% | ↗ |
| 52 | 2015 | Dr. Mark Kowalski Former Chief Medical Officer | 366.8K | 216.6K | — | 1.29M | — | 11.4K | 1.89M | 68.47% | ↗ |
| 53 | 2015 | Dr. Mark Kowalski Chief Medical Officer | 366.8K | 216.6K | — | 1.29M | — | 11.4K | 1.89M | 68.47% | ↗ |
| 54 | 2015 | Dr. Peter Lutwyche Chief Technology Officer | 287.2K | 152.7K | — | 1.29M | — | 11.8K | 1.74M | 74.09% | ↗ |
| 55 | 2015 | Dr. Michael Sofia Chief Scientific Officer | 323.9K | 100.0K | — | — | — | 6.1K | 430.0K | 0.00% | ↗ |
| 56 | 2015 | Mr. Patrick Higgins Former Chief Business and Commercial Operations Officer | 332.1K | 30.0K | — | — | — | 8.0K | 370.2K | 0.00% | ↗ |
| 57 | 2014 | Dr. Mark Murray President and Chief Executive Officer | — | 180.0K | — | — | — | 38.8K | 1.09M | 0.00% | ↗ |
| 58 | 2014 | Dr. Mark Murray President and Chief Executive Officer | 400.0K | 180.0K | — | 466.4K | — | 38.8K | 1.09M | 42.98% | ↗ |
| 59 | 2014 | Dr. Mark Murray President and CEO | 400.0K | 180.0K | — | 466.4K | — | 38.8K | 1.09M | 42.98% | ↗ |
| 60 | 2014 | Dr. Mike Abrams Executive Vice President and Chief Discovery Officer | 270.0K | 88.0K | — | — | — | 8.5K | 869.8K | 0.00% | ↗ |
| 61 | 2014 | Dr. Mark Kowalski Senior Vice President and Chief Medical Officer | — | 105.0K | — | — | — | 16.0K | 787.3K | 0.00% | ↗ |
| 62 | 2014 | Dr. Mark Kowalski Chief Medical Officer | 333.1K | 105.0K | — | 333.1K | — | 16.0K | 787.3K | 42.32% | ↗ |
| 63 | 2014 | Dr. Mark Kowalski Former Chief Medical Officer | 333.1K | 105.0K | — | 333.1K | — | 16.0K | 787.3K | 42.32% | ↗ |
| 64 | 2014 | Dr. Ian MacLachlan Former Executive Vice President and Former Chief Technical Officer | 322.9K | — | — | — | — | 15.1K | 640.5K | 0.00% | ↗ |
| 65 | 2014 | Dr. Peter Lutwyche Chief Technology Officer | 223.8K | 70.5K | — | 266.5K | — | 8.9K | 569.7K | 46.78% | ↗ |
| 66 | 2014 | Mr. Bruce Cousins Executive VP and Chief Financial Officer | 276.1K | 99.6K | — | — | — | 44.0K | 419.7K | 0.00% | ↗ |
| 67 | 2014 | Mr. Bruce Cousins EVP and CFO | 276.1K | 99.6K | — | — | — | 44.0K | 419.7K | 0.00% | ↗ |
| 68 | 2014 | Mr. Bruce Cousins Executive Vice President, Finance and Chief Financial Officer | 305.0K | 99.6K | — | — | — | 44.0K | 419.7K | 0.00% | ↗ |
| 69 | 2013 | Mr. Bruce Cousins EVP and CFO | 69.5K | 24.3K | — | 1.25M | — | 2.1K | 1.34M | 92.86% | ↗ |
| 70 | 2013 | Mr. Bruce Cousins Executive Vice President, Finance and Chief Financial Officer | 71.6K | 24.3K | — | — | — | 2.1K | 1.34M | 0.00% | ↗ |
| 71 | 2013 | Dr. Mark Murray President and CEO | 377.5K | 160.4K | — | — | — | 43.8K | 581.7K | 0.00% | ↗ |
| 72 | 2013 | Dr. Mark Murray President and Chief Executive Officer | — | 160.4K | — | — | — | 43.8K | 581.7K | 0.00% | ↗ |
| 73 | 2013 | Dr. Mark Kowalski Chief Medical Officer | 128.6K | 36.2K | — | 261.8K | — | 3.9K | 430.5K | 60.81% | ↗ |
| 74 | 2013 | Dr. Mark Kowalski Senior Vice President and Chief Medical Officer | — | 36.2K | — | — | — | 3.9K | 430.5K | 0.00% | ↗ |
| 75 | 2013 | Dr. Ian MacLachlan Former Executive Vice President and Former Chief Technical Officer | 315.0K | 113.7K | — | — | — | 9.4K | 429.0K | 0.00% | ↗ |
| 76 | 2013 | Dr. Peter Lutwyche Chief Technology Officer | 233.0K | 71.4K | — | — | — | 7.0K | 311.4K | 0.00% | ↗ |
| 77 | 2013 | Dr. Mike Abrams Executive Vice President and Chief Discovery Officer | — | — | — | — | — | — | — | — | ↗ |
| 78 | 2012 | Dr. Mark Murray President and Chief Executive Officer | — | 348.0K | — | — | — | 62.0K | 925.8K | 0.00% | ↗ |
| 79 | 2012 | Dr. Ian MacLachlan Former Executive Vice President and Former Chief Technical Officer | 295.0K | 295.2K | — | — | — | 8.9K | 717.6K | 0.00% | ↗ |
| 80 | 2012 | Dr. Mark Kowalski Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 81 | 2012 | Mr. Bruce Cousins Executive Vice President, Finance and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 82 | 2012 | Dr. Mike Abrams Executive Vice President and Chief Discovery Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lindsay Androski | President, Chief Executive Officer & Chairman | 736.6K | female |
| Tuan Nguyen | Chief Financial Officer | 651.9K | male |
| Andrew J. Sung | General Counsel | — | male |
| R. Hector Mackay-Dunn | Corporate Secretary | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABUS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
